Filtered By:
Specialty: Neurosurgery

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 602 results found since Jan 2013.

SEIZURES AND CORTICAL LESIONS IN MOG IgG ASSOCIATED SYNDROMES
Conclusion Patients with MOG IgG associated disease are more likely to have seizures (P<0.008, Fisher's test) and cortical MRI changes compared to AQP4IgG +ve cases. This may further support the view that the two are different diseases.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Hamid, S., Saviour, M., Much, K., Elsone, L., Bhojak, M., Jacob, A. Tags: Immunology (including allergy), Cranial nerves, Epilepsy and seizures, Multiple sclerosis, Neuroimaging, Ophthalmology ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Rituximab use in a patient with anti-ri positive opsoclonus myoclonus syndrome
We describe a patient with OMS, who had a previous (and completely treated) diagnosis of Breast cancer more than 10 years ago, who presented with features of dizziness, opsoclonus, generalised myoclonus and truncal ataxia. Investigations revealed positive anti-Ri antibodies, but comprehensive screen for an underlying malignancy was negative. Patient was initially treated with intravenous immunoglobulins (IVIg) with good response. However, despite this patient had a further relapse which required hospitalisation with ventilator support and another course of IVIg. A second relapse was treated with pulsed IV cyclophosphamide ...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Sadalage, G., Bowen, J., Nightingale, S., Jacob, S. Tags: Immunology (including allergy), Cranial nerves, Drugs: CNS (not psychiatric), Ophthalmology, Adult intensive care, Drugs: musculoskeletal and joint diseases ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

A novel monitoring system for hypothermia in multiple sclerosis: a case study
We present a case in which a novel monitoring garment was designed by a patient's partner, in response to recurrent episodes of hypothermia. The patient had three acute admissions to hospital with hypothermia over three months. Her temperature was found to be as low as 29.3°C on these occasions. This was attributed to thermoregulatory failure secondary to MS. No other cause was identified. The patient's partner who was a physics teacher, designed a system to monitor and treat the hypothermic episodes at home, thus avoiding hospital admission. The system consisted of a temperature sensor to continuously transmit recordi...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Kamalathasan, S., Ford, H. Tags: Immunology (including allergy), Coma and raised intracranial pressure, Multiple sclerosis ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Natalizumab reduces ms relapse rates in uk top patients
Conclusions Notwithstanding the inherent limitations of this small-cohort analysis, natalizumab reduces relapse rate post IFN or GA. Supported by Biogen. Disclosures: RN: grant and conference travel support from Biogen; JH: employee of and holds stock/stock options in Biogen.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Nicholas, R., Hanna, J. Tags: Immunology (including allergy), Infection (neurology), Multiple sclerosis ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Daclizumab hyp vs im interferon beta-1a in ms: neda results from decide
Conclusions A significantly greater percentage of patients treated with DAC HYP than with IM IFN beta-1a achieved NEDA. Sponsors: Biogen, AbbVie Biotherapeutics.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Kappos, L., Havrdova, E., Giovannoni, G., Khatri, B., Greenberg, S., Wang, P., Elkins, J., Giannattasio, G. Tags: Immunology (including allergy) ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Daclizumab hyp in multiple sclerosis: 3-year results from selected
Conclusions Efficacy of DAC HYP was sustained over 3 years in RRMS patients, supporting long-term maintenance therapy with DAC HYP. Sponsors: Biogen, AbbVie Biotherapeutics.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Radue, E.-W., Giovannoni, G., Gold, R., Selmaj, K., Havrdova, E., Stefoski, D., Sprenger, T., Montalban, X., Riester, K., Ozen, G. Tags: Immunology (including allergy), Multiple sclerosis ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

The newcastle experience of anti-mog associated disease
The original reports of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies describe a predominant association with acute disseminated encephalomyelitis in children and with neuromyelitis optica spectrum disease (NMOSD) in adults. More recent studies broaden the spectrum of associated disorders to include recurrent optic neuritis and a picture similar to CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids). We performed a retrospective case note review of the presentation, imaging, laboratory findings and response to treatment of a group of 12 patients, aged 3&ndash...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Bolton, C., Chapman, J., Ledingham, D., Lewis-Smith, D., Spyropoulos, A., Guadagno, J., Duddy, M. Tags: Immunology (including allergy), Cranial nerves, Drugs: CNS (not psychiatric), Multiple sclerosis, Neuromuscular disease, Peripheral nerve disease, Ophthalmology ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Ocrelizumab in primary progressive ms: the oratorio study
Conclusions OCR is the first investigational therapy to meet key efficacy outcomes with a favourable safety profile in a Phase III PPMS study. Sponsored by F. Hoffmann-La Roche Ltd.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Giovannoni, G., Arnold, D., Bar-Or, A., de Seze, J., Hemmer, B., Montalban, X., Rammohan, K., Wolinsky, J., on behalf of the ORATORIO clinical investigators Tags: Immunology (including allergy) ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

OCRELIZUMAB VS INTERFERON {beta}-1A IN RELAPSING MS: TWO STUDIES
Conclusions OCR demonstrated significantly superior efficacy vs IFNβ-1a and a favourable safety profile in RMS patients.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Silber, E., Arnold, D., Bar-Or, A., Comi, G., Hartung, H., Hauser, S., Lublin, F., Selmaj, K., Traboulsee, A., Kappos, L., on behalf of the OPERA I and II clinical investigators Tags: Immunology (including allergy) ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Can liquorice make steroids more palatable in multiple sclerosis?
Conclusion We have shown that administration of liquorice prior to steroid therapy reduces the severity of the metallic taste by half and was beneficial in over 90% of patients.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Low, S., Chataway, J. Tags: Immunology (including allergy), Multiple sclerosis ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Complement activation in multiple sclerosis and nmo spectrum disorders
MS and NMOSD are inflammatory CNS diseases and early manifestations can be similar creating management problems, since MS drugs may be ineffective and/or worsen NMOSD. MR imaging and AQP4-Abs provide diagnostic information in most NMOSD cases, but a minority remain AQP4-Ab-negative; underlining the need for alternative diagnostic biomarkers. Complement (C) activation is a core pathological feature in both. We have investigated whether plasma C analytes can distinguish MS from NMOSD. Plasma from 53 NMOSD, 49 MS and 69 controls was tested in 2 multiplex assays: the first measuring 5 C activation products and the second compr...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Luppe, S., Hakobyan, S., Evans, D., Harding, K., Loveless, S., Robertson, N., Morgan, B. P. Tags: Immunology (including allergy), Drugs: CNS (not psychiatric), Multiple sclerosis ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Usage and equitability of multiple sclerosis dmt in england
Patients with MS are drawn from every stratum of society. It is important that patients have equitable access to disease modifying treatments (DMT). Patient registry data on 3490 subjects from 16 centres in England from the past 26 months of the TONiC study were aligned, by postcode, with indices of deprivation, from the Office of National Statistics. These indices and disease factors were cross-tabulated with DMT usage. The sample's sex and disease type distribution were representative of a typical MS population. 53% were on DMT (22% injectables, 13% natalizumab, 9% orals, 9% other). 92% of rapidly evolving, 63% of relaps...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Mills, R., Young, C., on behalf of TONiC Investigators Tags: Immunology (including allergy), Multiple sclerosis ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Intracerebral haemorrhage in normotensive patient with probable neurosaroidosis
Conclusion Vasculopathy in neurosarcoidosis results from granulomatous destruction of vessel walls, perivascular inflammation and/or steroid-induced collagen fragility. This case highlights an under-recognised and serious complication that may occur as a result. Aggressive disease suppression via immunomodulatory treatment may help minimise the risk of haemorrhagic events.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Mirza, F., Das, J., Chauhan, V., Cooper, P., Pace, A. Tags: Immunology (including allergy), Neuroimaging, Radiology, Vascularitis, Radiology (diagnostics) ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Gilenya patient characteristics in the uk
Conclusion More than 65% of patients escalated to Gilenya after first failure of DMT. 91.9% of patients commencing on Gilenya in the UK in real world clinical practice remained on treatment after 1 year.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Mazibrada, G., Garcia-Ganuza, P. P. Tags: Immunology (including allergy), Multiple sclerosis ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Ms fine study: gilenya real world experience in the uk
Conclusion Fingolimod is shown to be an effective therapy in patients with highly active RRMS in real world clinical practice in the UK.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Mazibrada, G., Garcia-Ganuza, P. P. Tags: Immunology (including allergy), Multiple sclerosis ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research